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Certain viruses, bacteria, fungi and parasites target dendritic cells through the interaction with the cellular attachment factor DC-SIGN, making
this C-type lectin an attractive target for therapeutic intervention. Studies on DC-SIGN function would be greatly aided by the establishment of a
mouse model, however, it is unclear if the murine (m) homologue of human (h) DC-SIGN also binds to pathogens. Here, we investigated the
interaction of mDC-SIGN, also termed CIRE, with the Ebolavirus glycoprotein (EBOV-GP), a ligand of hDC-SIGN. We found that mDC-SIGN
neither binds EBOV-GP nor enhances infection by reporterviruses pseudotyped with EBOV-GP. Analysis of chimeras between mDC-SIGN and
hDC-SIGN provided evidence that determinants in the carbohydrate recognition domain and in the neck domain of mDC-SIGN inhibit a
functional interaction with EBOV-GP. Moreover, mDC-SIGN was found be monomeric, suggesting that lack of multimerization, which is believed
to be required for efficient pathogen recognition by hDC-SIGN, might be one factor that prevents binding of mDC-SIGN to EBOV-GP. Our results
suggest that mDC-SIGN on murine dendritic cells is not an adequate model for pathogen interactions with hDC-SIGN.
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Dendritic cells (DCs) are key to the establishment of
effective innate and adaptive immune responses against
invading pathogens (Banchereau and Steinman, 1998). The
C-type (i.e., calcium-dependent) lectin DC-SIGN, which is
expressed at high levels on DCs, might play an important role
in these processes (Geijtenbeek et al., 2000b, 2000c). DC-
SIGN recognizes high-mannose glycans and fucose containing
structures present on the surface of pathogens and self antigens
(Feinberg et al., 2001; Guo et al., 2004). Binding of DC-SIGN
to pathogens can lead to antigen uptake and processing for
MHC presentation (Engering et al., 2002). In contrast, DC-
SIGN binding to the natural ligands ICAM-2 on endothelial
cells (Geijtenbeek et al., 2000a), and ICAM-3 on T-cells
(Geijtenbeek et al., 2000c), might promote establishment of0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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presentation, respectively. Despite its role as an antigen uptake
receptor, a variety of pathogens, among them human immu-
nodeficiency virus (HIV), Ebolavirus (EBOV) and dengue
virus, misuse DCs via DC-SIGN to promote their dissemina-
tion in the host (van Kooyk and Geijtenbeek, 2003). The
importance of DC-SIGN for pathogen spread is particularly
underlined by recent reports demonstrating an association
between polymorphisms in the DC-SIGN gene and suscepti-
bility to dengue virus and HIV infection (Liu et al., 2004;
Martin et al., 2004; Sakuntabhai et al., 2005).
For the analysis of DC-SIGN function and the evaluation of
potential inhibitors, a mouse model for human (h) DC-SIGN on
DCs is highly desirable. Therefore, the characterization of
murine (m) homologues of hDC-SIGN is an important task.
Baribaud and colleagues first reported the identification of a
DC-SIGN variant in mice, which they termed mDC-SIGN
(Baribaud et al., 2001). This molecule was shown to bind to
HIV but failed to enhance infectivity for adjacent T-cells
(Baribaud et al., 2001). Subsequent studies demonstrated,6) 482 – 491
www.e
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out of five murine homologues of hDC-SIGN (Parent et al.,
2002; Park et al., 2001) and is expressed on macrophages but
not on mDCs (Geijtenbeek et al., 2002a; Kang et al., 2003).
One of the murine isoforms of hDC-SIGN was indeed shown
to be expressed on mDCs and is believed to constitute the
murine homologue of hDC-SIGN (Caminschi et al., 2001; Park
et al., 2001). This variant is now termed mDC-SIGN or CIRE.
While it has been demonstrated that mSIGNR1 binds to
pathogens and to murine ICAM2 (Geijtenbeek et al., 2002a;
Kang et al., 2003; Takahara et al., 2004; Taylor et al., 2004)
and plays a role in the defense against pathogens (Koppel et al.,
2005c; Lanoue et al., 2004), the ligands and thus the function
of mDC-SIGN are unclear (Koppel et al., 2005b).
mDC-SIGN and hDC-SIGN exhibit a similar domain
organization (Caminschi et al., 2001; Park et al., 2001). The
N-terminus of both lectins is located in the cytoplasm and is
followed by a transmembrane domain, which inserts the proteins
into the cytoplasmic membrane. The extracellular domain
consists of a neck region followed by a carbohydrate recognition
domain (CRD) containing an EPN motif required for binding to
mannose containing carbohydrates (Koppel et al., 2005b).
However, also differences between mDC-SIGN and hDC-SIGN
sequences are apparent. Maybe most strikingly, the 191 amino
acids encompassing hDC-SIGN neck domain consists of 7.5
blocks of a repeating sequence and mediates tetramerization,
which is likely required for high-avidity binding to pathogens
(Feinberg et al., 2001;Mitchell et al., 2001). In contrast, the neck
domain of mDC-SIGN only comprises a 29 amino acid sequence
(Caminschi et al., 2001; Park et al., 2001) sharing considerable
homology with that of a single repeat unit in the neck domain of
hDC-SIGN, and its function is unknown. Despite similarities in
expression and domain organization, mDC-SIGN and hDC-
SIGN might therefore exhibit differences in the interaction with
pathogens.
Here, we analyzed mDC-SIGN interactions with the
glycoprotein (GP) of EBOV, a ligand of hDC-SIGN. We show
that mDC-SIGN does not bind to EBOV-GP and does not
enhance EBOV-GP-dependent infection. Analysis of chimeric
proteins between human and mDC-SIGN revealed that
determinants in the neck and CRD of mDC-SIGN prevent a
functional interaction with EBOV-GP. Finally, evidence was
obtained that cellular mDC-SIGN is monomeric, which might
generally impede efficient binding to multivalent ligands like
viral GPs.
Results
mDC-SIGN does not interact with the GPs of EBOV, severe
acute respiratory syndrome coronavirus (SARS-CoV) and
HIV-1
In order to analyze mDC-SIGN interactions with EBOV-
GP, we thought to transiently express the lectin on 293T cells.
However, in contrast to published data (Takahara et al.,
2004), we found that mDC-SIGN is not expressed on 293T
cells to appreciable levels (Fig. 3), while robust expressionwas observed on Chinese hamster ovary (CHO) cells (Fig. 3).
CHO cells stably expressing mDC-SIGN or hDC-SIGN were
therefore used for further analysis. In order to investigate
lectin mediated enhancement of EBOV-GP driven infection,
these cells were inoculated with lentiviral reporterviruses
pseudotyped with the EBOV-GP of the Zaire strain (so called
pseudotypes). These viruses encode the luciferase gene in
place of nef and luciferase is only expressed upon successful
integration of the proviral genome into the host cell
chromosome. In agreement with previous results (Alvarez et
al., 2002; Baribaud et al., 2002b; Simmons et al., 2003),
expression of hDC-SIGN strongly enhanced EBOV-GP
driven infection compared to control cells (Fig. 1A).
Augmentation of infection was specific, since pretreatment
with mannan, a mannose polymer produced in yeast,
diminished infection to levels observed with control cells.
In contrast, expression of mDC-SIGN did not enhance
EBOV-GP-dependent infection (Fig. 1A). Comparable results
were obtained when binding of soluble EBOV-GP to mDC-
SIGN and hDC-SIGN was analyzed (Fig. 1B, upper panel),
indicating that mDC-SIGN does not interact with EBOV-GP.
Similarly, mDC-SIGN failed to bind to soluble SARS-CoV
spike (S) protein and HIV-1 gp120 (Fig. 1C), further
underlining that mDC-SIGN exhibits defects in the capture
of pathogens known to bind to hDC-SIGN. Finally, induced
expression of mSIGNR1 on 293 T-REx cells augmented
binding of EBOV-GP (Fig. 1B, lower panel) and, in
agreement with our previous results (Marzi et al., 2004),
enhanced EBOV-GP-dependent infection (data not shown),
indicating that hDC-SIGN and mSIGNR1, but not mDC-
SIGN, function as attachment factors for pathogens.
Expression of mDC-SIGN-hDC-SIGN chimeras
In order to investigate why mDC-SIGN (CCCC), despite its
considerable sequence homology with hDC-SIGN (DDDD),
does not interact with EBOV-GP, we analyzed chimeras
between both proteins. Fragments containing the cytoplasmic
domain (variant CDDD), the cytoplasmic and transmembrane
domain (variant CCDD) and the cytoplasmic, transmembrane
and neck domain of mDC-SIGN (variant CCCD) were
introduced into hDC-SIGN and vice versa (variants DCCC,
DDCC, DDDC) (Fig. 2). A C-terminal AU1 antigenic tag was
added to all chimeras in order to allow detection of expression.
Expression studies demonstrated that constructs harboring at
least the mDC-SIGN CRD were not appreciably expressed on
the surface of 293T cells (data not shown). Therefore, CHO
cells were generated that stably expressed chimeras containing
the mDC-SIGN CRD. Staining with a monoclonal antibody
specific for the mDC-SIGN CRD indicated that these
constructs were expressed robustly and to comparable degrees,
with the exception of chimera DDCC, which exhibited reduced
expression (Fig. 3, upper panel). In contrast, when an antibody
reactive against the AU1 antigenic tag was used for staining,
only expression of DDDC could be detected (Fig. 3, upper
panel). These observations suggest that the C-terminus of
mDC-SIGN (in chimeras CCCC, DCCC and DDCC) is not
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conformation, while the introduction of the hDC-SIGN neck
domain (chimera DDDC) seems to alter the spatial orientation
of the mDC-SIGN CRD, thereby making its C-terminus
accessible to the antibody. In turn, expression of all constructs
harboring the hDC-SIGN CRD (CDDD, CCDD and CCCD)
was readily detected on transfected 293T cells by staining with
the anti AU1 antibody, albeit expression of CCCD was reducedFig. 1. mDC-SIGN does not interact with EBOV-GP. (A) mDC-SIGN does no
augment EBOV-GP-dependent infection. CHO cell lines stably expressing the
indicated lectins or CHO control cells were preincubated with PBS or mannan
and inoculated with pseudotypes bearing EBOV-GP. Luciferase activity in cel
lysates was determined 3 days after infection. The results of a representative
experiment are shown, similar results were obtained in two independen
experiments. Error bars indicate standard deviation (SD). (B and C) mDC-SIGN
does not bind to soluble viral GPs. CHO cells or 293 T-REx cells expressing the
indicated lectins were incubated with culture supernatants containing chimeric
proteins in which the EBOV-GP1 subunit, the SARS-CoV-S1 subunit or HIV-1
gp120 were fused to the Fc portion of human immunoglobulin, and bound
protein was detected by FACS analysis. Binding to lectin-expressing cells is
shown in white, while binding to control cells is shown in black. Representative
experiments are presented, comparable results were obtained in two independen
experiments.
Fig. 2. Schematic representation of the chimeras between mDC-SIGN/CIRE
(‘‘C’’) and hDC-SIGN (‘‘D’’). CD, cytoplasmic domain; TM, transmembrane
domain; neck, neck domain; CRD, carbohydrate recognition domain.(Fig. 3, lower panel). In contrast, no staining was observed
with the anti mDC-SIGN antibody (Fig. 3, lower panel), which
is in agreement with the specificity of this antibody for the
mDC-SIGN CRD (Caminschi et al., submitted for publication).
The neck domain and the CRD of mDC-SIGN impede the
interaction with EBOV-GP
We next investigated the ability of the chimeric proteins to
enhance infection by EBOV-GP bearing pseudotypes. All
lectin-expressing cells analyzed were readily permissive to
infection driven by the GP of vesicular stomatitis virus (VSV-
G) and, in agreement with previous results (Simmons et al.,
2003), lectin expression did not modulate VSV-G-dependent
infection (Fig. 4). In contrast, hDC-SIGN but not mDC-SIGN
expression efficiently and specifically augmented EBOV-GP
mediated infectious entry, while all chimeras harboring the
mDC-SIGN CRD did not enhance EBOV-GP-dependent
infection (Fig. 4, left panel). These results suggest that the
mDC-SIGN CRD does not recognize EBOV-GP and that this
defect cannot be rescued by linking the CRD to the hDC-
SIGN neck. Insertion of the mDC-SIGN cytoplasmic domain
and transmembrane domain into hDC-SIGN was compatible
with enhancement of infection, while the additional insertion
of the mDC-SIGN neck abrogated augmentation of infection
(Fig. 4, right panel). However, the respective variant, CCCD,
was not efficiently expressed on 293T cells (Fig. 3, lowert
l
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Fig. 3. Expression of chimeric lectins. Expression of the indicated lectins on stably transfected CHO cells (upper panel) and transiently transfected 293T cells (lower
panel) was analyzed by FACS. Monoclonal antibodies directed against the C-terminal AU1 antigenic tag or against the mDC-SIGN protein were used for staining as
indicated. The results of a single experiment is shown, the results were confirmed in at least two independent experiments.
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cell line stably expressing this lectin to appreciable levels
(Fig. 5A). Again, CCCD was defective in the interaction with
EBOV-GP bearing pseudotypes (data not shown), suggesting
that the mDC-SIGN neck prevents the interaction with virion-
associated EBOV-GP.Fig. 4. The neck domain and CRD of mDC-SIGN are not compatible with enhancem
lectins (left panel) or 293T cells transiently expressing the indicated lectins (right pa
luciferase activity in cellular lysates was determined 3 days after infection. A represen
experiments. Error bars indicate SD.To further characterize the impact of the mDC-SIGN neck
domain on the interaction with EBOV-GP, we assessed binding
of soluble EBOV-GP to chimeras, in which the CRDs were
exchanged between hDC-SIGN and mDC-SIGN (chimeras
CCCD, DDDC). Expression of all chimeras was readily
detectable on stably transfected CHO cells (Fig. 5A). However,ent of EBOV-GP-dependent infection. CHO cells stably expressing the indicated
nel) were inoculated with EBOV-GP or VSV-G harboring pseudotypes and the
tative experiment is presented, similar results were obtained in two independent
Fig. 5. Replacement of the mDC-SIGN CRD with the CRD of hDC-SIGN confers binding to soluble EBOV-GP. (A) Expression of chimeric lectins. The expression
of the indicated lectins on stably transfected CHO cells (white) was analyzed by FACS upon staining with hDC-SIGN (for detection of DDDD and CCCD) or mDC-
SIGN (for detection of DDDC) specific antibodies. CHO cells stably transfected with empty vector served as negative controls (black). A single experiment is
shown, the results are representative for at least two independent experiments. (B) Binding of soluble EBOV-GP to chimeric lectins. Binding of a control Ig protein
and of soluble EBOV-GP to CHO lines stably expressing the indicated lectins (white) or control CHO cells (black) was analyzed. A representative experiment is
shown, similar results were obtained in an independent experiment.
Fig. 6. Cellular mDC-SIGN is monomeric. Lysates from CHO cells (A) or
293T cells (B) expressing the indicated lectins were separated by SDS gel-
electrophoresis under reducing and non-reducing conditions, and lectin
expression was analyzed by Western blot. Comparable results were obtained
in four independent experiments.
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cells bound to EBOV-GP, while no binding to cells stably
transfected with chimera DDDC was detected (Fig. 5B). These
results indicate that the mDC-SIGN neck domain interferes
with the interaction with virion-associated EBOV-GP trimers,
but is compatible with binding to soluble EBOV-GP. In
contrast, the neck domain of hDC-SIGN did not rescue
EBOV-GP recognition by the mDC-SIGN CRD (Fig. 5B),
indicating that the CRD is not capable of binding virion-
associated or soluble EBOV-GP.
Cellular mDC-SIGN is monomeric
The neck domain of hDC-SIGN drives tetramerization of the
protein, which is required for high-avidity binding to ligands
displaying a high number of appropriate glycans on their surface
(Feinberg et al., 2005; Mitchell et al., 2001). We therefore
investigated if mDC-SIGN also forms multimers. SDS gelelec-
trophoresis under reducing and non-reducing conditions
revealed that hDC-SIGN forms multimers (Figs. 6A, B), as
expected from previous reports (Feinberg et al., 2005; Mitchell
et al., 2001), while no evidence for multimerizationwas obtained
for mDC-SIGN (Fig. 6A). Absence of multimerization was
linked to the presence of the mDC-SIGN neck domain (variants
DDDC, CCCD; Figs. 6A, B), suggesting that, apart of
determinants in the CRD, the absence of neck domain induced
mDC-SIGN clustering on the cell surface might prevent this
protein from interacting with EBOV-GP.
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Here, we show that in contrast to hDC-SIGN, mDC-SIGN
does not interact with EBOV-GP and other viral GPs.
Determinants which inhibit the interaction were mapped to
the neck domain and the CRD. Moreover, evidence was
obtained that cellular mDC-SIGN is monomeric, which might
generally hamper efficient recognition of multivalent ligands.
Our results suggest, that mDC-SIGN expressed on murine DCs
is not suitable as a model for hDC-SIGN function.
hDC-SIGN and the related lectin DC-SIGNR (also termed
L-SIGN) (Bashirova et al., 2001; Po¨hlmann et al., 2001c) are
encoded by adjacent genes located on chromosome 19p13 and
share 77% amino acid sequence identity. Although hDC-SIGN
exhibits an extended carbohydrate specificity compared to DC-
SIGNR (Guo et al., 2004), both lectins recognize high-
mannose glycans and interact with much the same ligands
(Baribaud et al., 2002a; van Kooyk and Geijtenbeek, 2003).
However, DC-SIGNR is not expressed on DCs, but has been
detected in the endothelium of liver and lymph node sinusoids
as well as in placental villi (Bashirova et al., 2001; Po¨hlmann et
al., 2001c). DC-SIGNR might capture pathogens present in
blood and lymph fluid and might promote infection of adjacent
cells or of the lectin-expressing cells. Thus, hDC-SIGN and the
related receptor DC-SIGNR facilitate attachment of pathogens
and might promote dissemination of pathogens in infected
individuals (Po¨hlmann et al., 2001a).
Albeit controversial findings regarding the importance of
hDC-SIGN for pathogen interactions with DCs have been
reported (Geijtenbeek et al., 2000b; Gummuluru et al., 2003;
Wu et al., 2002), several recent studies strongly support an
important function of hDC-SIGN in pathogen spread (Arrighi
et al., 2004a, 2004b; Hu et al., 2004). Maybe most strikingly, a
polymorphism in the hDC-SIGN promoter has been shown to
modulate the susceptibility to primary dengue virus infection
and the risk of HIV infection upon parenteral transmission
(Martin et al., 2004; Sakuntabhai et al., 2005). Similarly, a
polymorphism in the hDC-SIGN neck domain was found to be
associated with reduced risk of HIV infection (Liu et al., 2004).
These observations underline that hDC-SIGN is an attractive
target for therapeutic intervention and call for the development
of small animal models to analyze DC-SIGN function and to
test potential inhibitors.
Establishment of a mouse model for hDC-SIGN interac-
tions with pathogens is particularly desirable. However, such
efforts are complicated by the expression of five DC-SIGN
homologues in mice, which are termed mDC-SIGN and
mSIGNR1 to mSIGNR4 (Park et al., 2001). The genes for the
murine isoforms of hDC-SIGN are located in the same
chromosomal locus and encode proteins with a comparable
domain organization (Koppel et al., 2005b). However, the
neck region of these proteins is of variable length and could
not be detected in mSIGNR2, which also does not contain a
transmembrane domain and might be secreted (Park et al.,
2001). All lectins except mSIGNR4 contain a EPN motif in
the CRD, suggesting that they might bind to mannosylated
ligands (Koppel et al., 2005b). Indeed, both mSIGNR1 andmSIGNR3 were found to interact with yeast-derived zymosan
particles and binding was inhibited by mannan (Takahara et
al., 2004), and it has been demonstrated that mSIGNR1
exhibits specificity for high-mannose carbohydrates (Galus-
tian et al., 2004; Koppel et al., 2005a). mSIGNR1 was also
shown to capture blood-borne pathogens like HIV and to
interact with ICAM-2 (Baribaud et al., 2001; Geijtenbeek et al.,
2002a; Takahara et al., 2004). These findings are complemen-
ted by our observation that mSIGNR1 binds to EBOV-GP (Fig.
1A) and augments EBOV-GP-dependent entry (Marzi et al.,
2004), suggesting that this lectin might be a functional
equivalent of hDC-SIGN. However, the expression pattern of
mSIGNR1, which is found on macrophages in lymph nodes
and spleen as well as on liver sinusoidal endothelial cells,
resembles that of DC-SIGNR (Koppel et al., 2005b). In turn,
mDC-SIGN was detected on plasmacytoid preDCs and is the
only known murine DC-SIGN isoform expressed on DCs
(Caminschi et al., 2001; O’Keeffe et al., 2002), indicating that
mDC-SIGN is the murine homologue of hDC-SIGN. However,
previous studies did not detect binding of mDC-SIGN to
mannosylated ligands (Takahara et al., 2004), suggesting that
the carbohydrate specificity of mDC-SIGN differs from that of
hDC-SIGN. Our observation that mDC-SIGN fails to complex
EBOV-GP, SARS-CoV-S and HIV-1 gp120 (Figs. 1B, C)
corroborates these findings and suggests that mDC-SIGN
might not function as an adhesion receptor for pathogens and
is thus not suitable as a model for DC-SIGN engagement by
pathogens.
Which determinants impede pathogen binding to mDC-
SIGN? The finding that the introduction of the mDC-SIGN
CRD into hDC-SIGN abrogates binding to EBOV-GP, while
the converse exchange allows the interaction with soluble
EBOV-GP (Figs. 4, 5), indicates that the mDC-SIGN CRD is
not compatible with the recognition of pathogens. At present, it
is unclear, however, if lack of binding of mDC-SIGN to
EBOV-GP is due to the absence of the appropriate type of
glycans on EBOV-GP, or if the spatial orientation of the
glycans is not compatible with recognition by mDC-SIGN. In
this regard it is of interest, that despite the considerable
sequence identity between the CRDs of hDC-SIGN and mDC-
SIGN, several amino acid exchanges are found in the mDC-
SIGN sequences corresponding to the primary (Feinberg et al.,
2001; Geijtenbeek et al., 2002b) and secondary (Guo et al.,
2004) carbohydrate binding sites in hDC-SIGN (Fig. 7).
Particularly, the V351L exchange in the primary binding site
of mDC-SIGN might narrow the carbohydrate specificity of
this lectin, since V351 in hDC-SIGN is important for the
extended carbohydrate specificity of hDC-SIGN compared to
DC-SIGNR (Guo et al., 2004).
Another determinant which might prevent mDC-SIGN
from binding to EBOV-GP is the neck domain. Thus,
introduction of the cytoplasmic and transmembrane domains
of mDC-SIGN into hDC-SIGN was compatible with augmen-
tation of EBOV-GP-dependent infection, while the additional
introduction of the neck domain abrogated augmentation of
infection (Fig. 4), suggesting that the neck domain inhibits a
functional interaction with EBOV-GP bearing pseudovirions.
Fig. 7. The CRD of mDC-SIGN harbors amino acids exchanges in the primary and secondary ligand binding site as compared to hDC-SIGN. An alignment of the
CRDs of hDC-SIGN and mDC-SIGN is shown. Triangles mark key residues in the primary and circles indicate important residues in the secondary ligand binding
site of hDC-SIGN. Amino acid exchanges in the ligand binding sites of mDC-SIGN are boxed. A conserved EPN motif important for binding to mannose containing
carbohydrates is marked in bold. The numbering is shown relative to that of the full length proteins.
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SIGN was still capable of binding to soluble EBOV-GP (Fig.
5). This discrepancy might have several reasons. For one,
virion-associated and soluble EBOV-GP might exhibit slight
differences in glycosylation or exposure of carbohydrate
moieties. Second, it can formally not be excluded that the
expression of the respective variant was insufficient for
augmentation of infection, but allowed binding to soluble
GP. Third, the defect in multimerization exhibited by this
variant (Fig. 6B), which is most likely caused by the neck
domain, might prevent functional interactions with virion
associated GPs resulting in augmentation of infection, but
might be compatible with capture of soluble GP. Thus, the 191
amino acids comprising neck domain of hDC-SIGN consists
of repeating sequences that drive tetramerization, which is
critical for the efficient interaction with ligands modified with
a high number of appropriate glycans (Feinberg et al., 2005;
Mitchell et al., 2001). In contrast, the neck domain of mDC-
SIGN consists only of 29 amino acids, does not contain
repetitive elements and does not drive tetramerization (Fig.
6A), indicating that the neck domain of mDC-SIGN might
impede efficient binding to multivalent ligands by failing to
mediate lectin multimerization. In this regard it is of interest
that mSIGNR1 was shown to form oligomers (Kang et al.,
2003), further substantiating the importance of lectin multi-
merization for pathogen capture. Finally, a negative role of the
mDC-SIGN neck domain in pathogen binding might be
explained by inadequate spacing of the CRD. Thus, it has
been suggested that the neck domain of hDC-SIGN projects
the lectin domain about 200A˚ over the cellular membrane and
thereby prevents binding to ligands present in the same
membrane (Feinberg et al., 2005). The small neck domain of
mDC-SIGN, however, might orient the CRD in a way that
allows binding to ligands present in the same cellular
membranes, which might explain the absence of binding to
pathogens.
In summary, we provided evidence that mDC-SIGN is not
an attachment factor for pathogens and that features of the neck
domain and CRD might impede binding to multivalent ligands.
Further studies are required to define the natural ligands and
function of mDC-SIGN and to attain these goals the generation
and characterization of mDC-SIGN knock-out mice would be
particularly helpful.Materials and methods
Cell culture
293T cells were propagated in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), penicillin and streptomycin. 293 T-REx cells expressing
DC-SIGN and mSIGNR1 were described previously (Marzi et
al., 2004; Po¨hlmann et al., 2001b) and maintained in DMEM
medium containing 10% FBS, 50 Ag/ml zeocin (Invitrogen,
CA, USA), 2.5 Ag/ml blasticidin (Invitrogen, CA, USA),
penicillin and streptomycin. Expression was induced by
culturing the cells in medium containing 0.1 Ag/ml doxycycline
(SIGMA-Aldrich, Germany). 293 T-REx parental cells were
maintained in the same medium as lectin-expressing cell lines,
however, no zeocin was added. Chinese Ovary Hamster-KI
cells (CHO) were cultivated in RPMI 1640 medium containing
10% FBS, penicillin and streptomycin. Lectin-expressing CHO
cells were generated by transfection of CHO cells with
pcDNA3.1 Zeo (Invitrogen, CA, USA) plasmids harboring
the lectin ORFs employing FuGENE6 transfection reagent
(Roche, IN, USA) according to the manufacturer’s instructions.
Transfectants were allowed to recover for 24 h before selection
with 250 mg/ml zeocin (Invitrogen, CA, USA) commenced.
Three days later, the concentration of zeocin was increased to
500 mg/ml and the cells were maintained until outgrowth of
resistant cells was observed. The selected cells were analyzed
for lectin expression by fluorescence activated cell sorting
(FACS) as described below and cell populations expressing
high levels of lectin were isolated and expanded. All cells were
grown at 37 -C and 5% CO2.
Plasmid construction and in vitro mutagenesis
Expression plasmids encoding hDC-SIGN were described
previously (Po¨hlmann et al., 2001b). To construct mDC-
SIGN expression vectors, the ORF of mDC-SIGN (Gene-
Bank file AY049062) was amplified by PCR and cloned into
pcDNA3.1Zeo (Invitrogen, CA, USA). Chimeras between
hDC-SIGN and mDC-SIGN were generated by overlap
extension PCR mutagenesis. For convenient detection of lectin
expression, carboxy-terminal AU1 antigenic tags were added to
the ORFs by PCR mutagenesis. The GP expression plasmids
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described previously (Simmons et al., 2003). For expression of
soluble EBOV-GP, the extracellular part of the GP ORF was
fused to the Fc part of human IgG1 via PCR and cloned in
frame with the amino-terminal murine IgG kappa signal
peptide in the eukaryotic expression vector pAB61 (Birkmann
et al., 2001). All PCR amplified sequences were confirmed by
automated sequence analysis.
Analysis of lectin mediated enhancement of
EBOV-GP-dependent infection
Lentiviral pseudotypes bearing the GP of the EBOV
subspecies Zaire or VSV-G were generated as described
elsewhere (Simmons et al., 2003). In brief, 293T cells were
transiently cotransfected with pNL4-3 ER Luc (Connor et
al., 1995) and an expression plasmid for EBOV-GP or VSV-G
using the calcium phosphate method. The culture medium was
changed after 16 h and then harvested 48 h post transfection.
The supernatants were passed through 0.4 Am filters,
aliquotted and stored at 80 -C. Lectin mediated enhance-
ment of viral infection was assessed employing CHO
transfectants or transiently transfected 293T cells. To analyze
the impact of lectin expression on EBOV-GP or VSV-G
driven infection, the indicated cell lines were seeded in 96-
well plates and infected with the indicated pseudotypes
normalized for comparable infectivity. After overnight incu-
bation the infection medium was changed and the cells
cultivated for 3 days. Subsequently, the cells were lysed and
luciferase-activities determined using a commercially avail-
able kit (Promega, MA, USA).
Analysis of lectin expression by flow cytometry
To assess cell surface expression of lectins, fluorescence
activated cell sorting analysis (FACS) was performed. Trans-
fected CHO cells, 293T cells or doxycycline-induced T-REx
cell lines were harvested, washed and resuspended in ice-cold
FACS buffer (PBS with 3% FBS; 0.01% NaN3). Approxi-
mately 2  105 cells were incubated with either a monoclonal
antibody (MAb) specific for the AU1 tag (Covance, CA, USA),
or MAb 526 specific for hDC-SIGN (Baribaud et al., 2002b) at
a final concentration of 10 Ag/ml or rat MAb 5H10 (Caminschi
et al., submitted for publication) raised against a peptide
derived from the mDC-SIGN lectin domain in a total volume of
100 Al FACS buffer for 45 min on ice. Cells were washed and
incubated with phycoerythrin-conjugated anti-mouse IgG or
fluorescein-conjugated anti-rat IgG (both from Vector Labora-
tories, CA, USA) at a final concentration of 5 Ag/ml for 45 min
on ice. Thereafter, the cells were washed, reconstituted in
FACS buffer and analyzed by FACS employing a FACScalibur
flow cytometer (Becton Dickinson).
Binding of soluble viral glycoproteins to lectin-expressing cells
Soluble EBOV-GP-Ig or control-Ig were obtained from
supernatants of 293T cells transiently expressing theseproteins. The fusion proteins were concentrated by employ-
ing Centricon Plus-20 centrifugal filters (Millipore, USA).
To measure binding to lectin expressing or parental CHO
cells, comparable amounts of soluble protein, as judged by
Western blot analysis, were incubated with the different cell
lines for 45 min on ice. After washing with FACS buffer,
cells were stained with Cyan5-conjugated anti-human IgG
(Jackson ImmunoResearch, USA) at a final concentration of
150 Ag/ml for 45 min on ice. Cells were then washed,
reconstituted in FACS buffer and analyzed by flow-
cytometry using a FACScalibur flow cytometer (Becton
Dickinson).
Western blot analysis of lectin expression
Lysates from CHO cells stably expressing the indicated
lectins or control CHO cells were generated under reducing and
non-reducing conditions. For reducing conditions samples
were dissolved in sodium dodecyl sulphate (SDS)-Laemmli
buffer containing h-mercaptoethanol and boiled for 15 min at
95 -C, whereas under non-reducing conditions, cells were
lysed in 10 mM Tris–HCl, 1 mM EDTA, 1 mM PMSF and
0.5% TritonX100 for 60 min at 4 -C and diluted in SDS-
Laemmli buffer without h-mercaptoethanol. Samples were
separated via SDS gel-electrophoresis and transferred onto
nitrocellulose membranes (Schleicher and Schu¨ll, Germany).
The indicated lectins were detected by staining with AU1
specific MAb (1 Ag/ml final concentration) and a peroxidase-
conjugated anti-mouse IgG (Jackson ImmunoResearch, USA),
concentrated 0.3 Ag/ml. Chemiluminescence detection was
performed using a commercially available kit according to the
manufacturer’s protocol (ECL Western detection kit; Amer-
sham Pharmacia, Germany).
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